Belimumab, an anti-BAFF/BlyS monoclonal antibody, has demonstrated efficacy in clinical trials, reducing disease activity, flare rates, improving patient quality of life, and decreasing corticosteroid dependence, leading to its approval as the first targeted biologic therapy for SLE (7). Here, TNFSF13B is linked to systemic lupus erythematosus.